The U.S. Department of Health and Human Services (HHS) lacks “reasonable assurance” that states and healthcare providers are complying with the prohibition against subjecting drug manufacturers to payment of duplicate 340B discounts
…Medicare Payment Advisory Commission (MedPAC) researchers were “unable to attribute” evidence of higher drug spending at 340B hospitals on two types of
…The Medicare Payment Advisory Commission (MedPAC) will hear from its staff on Jan. 17 about whether the 340B program gives participating hospitals an incentive to
…The Centers for Medicare & Medicaid Services released policy guidance yesterday outlining “best practices” states should consider for avoiding duplicate Medicaid rebates and 340B discounts
…The Health Resources and Services Administration (HRSA) announced this morning that it has awarded the 340B Prime Vendor Agreement to Apexus LLC after a competitive bid process.
“The 340B Prime Vendor
…Welcome to the pilot issue of 340B Report. We’re so glad to have you aboard! And now, let’s get to the news.
Xspire Pharma, a privately held, specialty pharmaceutical company, owes refunds
…
×
*Sign up for news summaries and alerts from 340B Report